BioCentury | Apr 26, 2019
Emerging Company Profile

ProNeurogen: Angiotensin peptides for vascular cognitive impairment

By developing native and glycosylated forms of the angiotensin-(1-7) peptide for vascular cognitive impairment, ProNeurogen hopes to plug a treatment gap that repurposed Alzheimer's disease drugs have failed to fill. There are no therapies approved...
BC Innovations | Jan 19, 2018

After amyloid

As the Alzheimer’s field is slowly taking on the search for new targets outside of the β amyloid and tau hypotheses, researchers are ramping up exploration of new pathways and looking to the disease’s genetics...
BC Week In Review | Sep 5, 2016
Company News

Qaam Pharmaceuticals, Axovant Sciences deal

Qaam granted Axovant an exclusive license to IP that covers the combination of cholinesterase inhibitors with peripheral muscarinic receptor antagonists. Axovant said the combination could mitigate the peripheral side effects of cholinesterase inhibitors, which are...
BC Week In Review | Aug 3, 2015
Clinical News

Ladostigil: Interim Phase IIb data

Avraham said interim data from a double-blind, international Phase IIb trial in 210 MCI patients showed that once-daily 10 mg oral ladostigil for up to 2 years led to a positive trend on the primary...
BC Week In Review | Jul 27, 2015
Clinical News

Amyvid florbetapir: Clinical trial data

A study in 618 patients being evaluated for cognitive decline showed that PET imaging with Amyvid led to treatment management changes in 68% of patients in the immediate-feedback group vs. 56% of patients in the...
BC Extra | Jul 24, 2015
Clinical News

Lilly study links Amyvid to changes in treatment

Eli Lilly and Co. (NYSE:LLY) presented data showing that knowledge of amyloid status measured by PET imaging agent Amyvid florbetapir led to changes in the diagnosis and management of patients being evaluated for cognitive decline....
BC Week In Review | Feb 16, 2015
Clinical News

Masican masitinib: Phase III ongoing

AB Science said an IDMC recommended continuation of the double-blind, placebo-controlled, international Phase III AB09004 trial of once-daily oral masitinib based on a futility analysis performed after about 1/3 of the patients were enrolled and...
BC Week In Review | Jan 19, 2015
Clinical News

SYN120: Phase IIa started

Biotie and the non-profit Parkinson Study Group began the double-blind, placebo-controlled, U.S. Phase IIa SYNAPSE trial to evaluate once-daily SYN120 for 16 weeks in about 80 patients already treated with a stable dose of a...
BC Week In Review | Jul 14, 2014
Clinical News

Ladostigil: Phase IIb ongoing

Avraham said an independent expert committee concluded there were no serious or unexpected adverse events preventing continuation of a double-blind, placebo-controlled, international Phase IIb trial of ladostigil based on safety data from patients who have...
BioCentury | Apr 14, 2014
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/11 cls Agios Pharmaceuticals Inc. (NASDAQ:AGIO) JPMorgan Geoffrey Meacham Upgrade Overweight (from neutral) 22% $43.32 Meacham also raised his target to $55 from $40...
Items per page:
1 - 10 of 55